- Analyses reveal single standard dose efficacy from day 22 to day 90 post vaccination of 76% with protection not falling in this three-month period
- After the second dose vaccine efficacy from two standard doses is 82.4% with the 3-month interval being used in the UK. (82.4% effective, with a 95% confidence interval of 62.7% - 91.7% at 12+ weeks)
- Data supports the 4-12 week prime-boost dosing interval recommended by many global regulators
- Analyses of PCR positive swabs in UK population suggests vaccine may have substantial effect on transmission of the virus with 67% reduction in positive swabs among those vaccinated
Oxford coronavirus vaccine shows sustained protection of 76% during the 3-month interval until the second dose
Clinical Trials Coronavirus COVID-19 General Research
2 February 2021
Researchers at the University of Oxford have today published in Preprints with The Lancet an analysis of further data from the ongoing trials of the vaccine. In this, they reveal that the vaccine efficacy is higher at longer prime-boost intervals, and that a single dose of the vaccine is 76% effective from 22- to up to 90-days post vaccination.